Jump to content

MDMAT

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Aethyta (talk | contribs) at 05:59, 23 April 2015 (Category:Designer drugs). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

MDMAT
Clinical data
Pregnancy
category
  • ?
Routes of
administration		?
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • N-methyl-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-7-amine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H15NO2
Molar mass205.25 g/mol g·mol−1
3D model (JSmol)
  • C3c1cc2OCOc2cc1CCC3NC
  • InChI=1S/C12H15NO2/c1-13-10-3-2-8-5-11-12(15-7-14-11)6-9(8)4-10/h5-6,10,13H,2-4,7H2,1H3 ☒N
  • Key:MTRLJTZQUZHTJI-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

6,7-Methylenedioxy-N-methyl-2-aminotetralin (MDMAT) is a putative, non-neurotoxic, selective serotonin releasing agent (SSRA) and entactogen drug. It is the N-methylated derivative of MDAT, similarly to the relationship of MDMA to MDA or MDMAI to MDAI.[1][2] It has been sold online as a 'research chemical' since 2010.

See also

References

  1. ^ Chimica Therapeutica 1971;6(3):196.
  2. ^ Medicinal Chemistry Research 1996;6(6):412.


Retrieved from "https://en.wikipedia.org/w/index.php?title=MDMAT&oldid=658798060"